Clinical Trial Results: Open-Label Safety, PK, and Efficacy Trial of Sebetralstat (KVD900) in Pediatric Patients (Ages 2-11) With HAE Type I or II [Phase 3]

View source ↗

Summary

Phase 3 open-label trial assessing safety, pharmacokinetics, and efficacy of sebretalstat (KVD900) in pediatric patients with hereditary angioedema type I/II (a…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• sebretalstat (sebretalstat)

Snippet

Sponsor: KalVista Pharmaceuticals, Ltd. | Conditions: Hereditary Angioedema | Phase 3 | Status: COMPLETED | Results posted: 2026-08-05